Facing COVID Surge, China Revises Course To Support Imported mRNA Vaccines
Major Policy Shift Expected
Latest announcement from Shanghai government set to open foreign mRNA jabs to the arms of Chinese people, after months of stalling approvals.
You may also be interested in...
Long-term safety results from the mRNA COVID-19 vaccine’s Phase II trial in a Chinese population could pave the way for its approval in China, investigators say.
In this week's podcast edition of Five Must-Know Things: time runs out to scale the next patent cliff; Novartis searches for new blockbuster; Boehringer Ingelheim’s R&D spending pays off; Shanghai eyes mRNA vaccines as COVID cases rise; and the global pharma R&D pipeline hits new heights.
The largest-ever COVID-related lockdown in Shanghai is offering an indication of the effectiveness of current Chinese policies around current controls and domestic vaccines, as well as prompting consideration of future directions for control and treatment measures as the pandemic moves to the endemic phase.